VThunter
a database for single-cell screening of virus target cells in animal kingdom
Pig

Taxonomy: Cellular organisms; Eukaryota; Opisthokonta; Metazoa; Eumetazoa; Bilateria; Deuterostomia; Chordata; Craniata; Vertebrata; Gnathostomata; Teleostomi; Euteleostomi; Sarcopterygii; Dipnotetrapodomorpha; Tetrapoda; Amniota; Mammalia; Theria; Eutheria; Boreoeutheria; Laurasiatheria; Artiodactyla; Suina; Suidae; Sus; Sus scrofa,

Latin Name: Sus scrofa domestica

Tested tissues: Lung, Frontal, Occipital, Parietal, Hypothalamus, Temporal,

Data set information
Project Date Technology Tissue Condition Cell PMID/DOI
Vthunter_0046 2021.04 10X Genomics Lung Normal 21981 Link
Vthunter_0069 2021.04 10X Genomics Frontal Normal 8812 Link
Vthunter_0070 2021.04 10X Genomics Occipital Normal 6829 Link
Vthunter_0071 2021.04 10X Genomics Parietal Normal 6162 Link
Vthunter_0072 2021.04 10X Genomics Hypothalamus Normal 7302 Link
Vthunter_0073 2021.04 10X Genomics Temporal Normal 3145 Link
Vthunter_0074 2021.04 iDrop Lung Normal 13580 Link
Vthunter_1013 2019.12 10X Genomics Lung Normal 7465 Link
Vthunter_1014 2019.12 10X Genomics Lung Normal 3987 Link
Virus Virus Name GeneTop 5 cell types expressing viral receptor ordered by expression proportion
Dengue virus
Lung-B_Bcl11a+ : 100.00% ;
Lung-Cell_cycle : 100.00% ;
Lung-Mac_alv : 98.93% ;
Lung-Mac_inter : 97.85% ;
Lung-DC : 96.61% ;
Lung-Mac_alv : 82.77% ;
Lung-Peri : 76.00% ;
Sindbis virus
Lung-B_Bcl11a+ : 100.00% ;
Lung-Cell_cycle : 100.00% ;
Lung-Mac_alv : 98.93% ;
Lung-Mac_inter : 97.85% ;
Lung-DC : 96.61% ;
Rabies lyssavirus
Occipital-OL-EX-3 : 100.00% ;
Occipital-OL-EX-5 : 100.00% ;
Occipital-OL-IN-2 : 100.00% ;
Occipital-OL-IN-3 : 100.00% ;
Parietal-PL-EX-3 : 100.00% ;
Adeno-associated virus 9
Lung-B_Bcl11a+ : 100.00% ;
Lung-Cell_cycle : 100.00% ;
Lung-Mac_alv : 98.93% ;
Lung-Mac_inter : 97.85% ;
Lung-DC : 96.61% ;
Adeno-associated virus - 2
Lung-B_Bcl11a+ : 100.00% ;
Lung-Cell_cycle : 100.00% ;
Lung-Mac_alv : 98.93% ;
Lung-Mac_inter : 97.85% ;
Lung-DC : 96.61% ;
Lung-Mac_alv : 91.01% ;
Lung-Cell_cycle : 90.11% ;
Lung-ATI : 84.52% ;
Lung-EC_lymph : 81.82% ;
Lung-Macrophages : 80.00% ;
Adeno-associated virus - 3
Lung-B_Bcl11a+ : 100.00% ;
Lung-Cell_cycle : 100.00% ;
Lung-Mac_alv : 98.93% ;
Lung-Mac_inter : 97.85% ;
Lung-DC : 96.61% ;
Adeno-associated virus - 8
Lung-B_Bcl11a+ : 100.00% ;
Lung-Cell_cycle : 100.00% ;
Lung-Mac_alv : 98.93% ;
Lung-Mac_inter : 97.85% ;
Lung-DC : 96.61% ;
Classical swine fever virus
Lung-B_Bcl11a+ : 100.00% ;
Lung-Cell_cycle : 100.00% ;
Lung-Mac_alv : 98.93% ;
Lung-Mac_inter : 97.85% ;
Lung-DC : 96.61% ;
Human papillomavirus type 16
Lung-Cell_cycle : 100.00% ;
Lung-Mac_inter : 98.92% ;
Lung-Mac_alv : 98.02% ;
Lung-Cell_cycle : 96.91% ;
Lung-DC : 96.61% ;
Simian rotavirus A strain RRV
Lung-B_Bcl11a+ : 100.00% ;
Lung-Cell_cycle : 100.00% ;
Lung-Mac_alv : 97.26% ;
Lung-DC : 93.22% ;
Lung-Mac_inter : 90.86% ;
Lung-Mac_alv : 91.01% ;
Lung-Cell_cycle : 90.11% ;
Lung-ATI : 84.52% ;
Lung-EC_lymph : 81.82% ;
Lung-Macrophages : 80.00% ;
Lung-Secretory : 86.11% ;
Lung-Secretory : 85.28% ;
Lung-ATI : 84.95% ;
Lung-ATI : 83.87% ;
Lung-Secretory cells : 76.96% ;
Venezuelan equine encephalitis virus
Lung-B_Bcl11a+ : 100.00% ;
Lung-Cell_cycle : 100.00% ;
Lung-Mac_alv : 98.93% ;
Lung-Mac_inter : 97.85% ;
Lung-DC : 96.61% ;
Porcine reproductive and respiratory syndrome virus
Lung-Cell_cycle : 100.00% ;
Lung-Mac_inter : 98.92% ;
Lung-Mac_alv : 98.02% ;
Lung-Cell_cycle : 96.91% ;
Lung-DC : 96.61% ;
Influenza A virus
Lung-DC : 98.31% ;
Occipital-OL-EX-5 : 98.01% ;
Lung-B_Bcl11a+ : 97.87% ;
Lung-Mac_inter : 97.85% ;
Lung-EC_lymph : 97.73% ;
Lung-ATI : 96.77% ;
Lung-Mac_alv : 96.19% ;
Lung-EC_lymph : 90.91% ;
Lung-ATI : 90.52% ;
Lung-Mac_alv : 89.47% ;
Lung-Fibroblasts : 88.95% ;
Occipital-OL-EX-5 : 86.09% ;
Lung-Smooth muscle cells : 83.98% ;
Occipital-OL-EX-3 : 82.05% ;
Lung-Ciliated cells : 77.40% ;
Lung-Secretory cells : 75.76% ;
Vesicular stomatitis virus
Lung-DC : 98.31% ;
Occipital-OL-EX-5 : 98.01% ;
Lung-B_Bcl11a+ : 97.87% ;
Lung-Mac_inter : 97.85% ;
Lung-EC_lymph : 97.73% ;
Lung-Peri : 80.00% ;
Lung-ATII : 75.29% ;
Japanese encephalitis virus
Lung-Mo : 97.69% ;
Lung-Mo : 95.56% ;
Severe acute respiratory syndrome coronavirus 2
Lung-Macrophages : 97.07% ;
Lung-Fibroblasts : 95.32% ;
Lung-ATII : 95.20% ;
Lung-T cells : 89.64% ;
Lung-Smooth muscle cells : 88.10% ;
Lung-Mac_inter : 89.78% ;
Lung-B_Bcl11a+ : 80.85% ;
Occipital-OL-EX-5 : 75.50% ;
Lung-Mac_alv : 82.77% ;
Lung-Peri : 76.00% ;
Enterovirus B
Lung-Mac_inter : 96.77% ;
Lung-Mac_alv : 96.34% ;
Lung-DC : 91.53% ;
Lung-Mo : 89.02% ;
Lung-EC_lymph : 86.36% ;
Equid alphaherpesvirus 1
Lung-Natural killer cells : 94.44% ;
Lung-B_Jchain+ : 85.98% ;
Lung-B_Bcl11a+ : 85.11% ;
Lung-T cells : 84.23% ;
Lung-Cell_cycle : 79.12% ;
Lung-Mac_alv : 91.01% ;
Lung-Cell_cycle : 90.11% ;
Lung-ATI : 84.52% ;
Lung-EC_lymph : 81.82% ;
Lung-Macrophages : 80.00% ;
Gibbon ape leukemia virus
Lung-Ciliated cells : 94.43% ;
Lung-Mac_alv : 77.59% ;
Amphotropic murine leukemia virus
Lung-Ciliated cells : 94.43% ;
Feline leukemia virus strain B/lambda-B1
Lung-Ciliated cells : 94.43% ;
Lung-Mac_alv : 77.59% ;
Suid alphaherpesvirus 1
Lung-ATI : 92.69% ;
Lung-ATII : 85.05% ;
Lung-ATII : 80.89% ;
Lung-ATI : 80.00% ;
Lung-ATII : 79.86% ;
Human alphaherpesvirus 1
Lung-ATI : 92.69% ;
Lung-ATII : 85.05% ;
Lung-ATII : 80.89% ;
Lung-ATI : 80.00% ;
Lung-ATII : 79.86% ;
Lung-Secretory : 86.11% ;
Lung-Secretory : 85.28% ;
Lung-ATI : 84.95% ;
Lung-ATI : 83.87% ;
Lung-Secretory cells : 76.96% ;
Lung-ATI : 82.58% ;
Lung-ATI : 80.21% ;
Lung-ATI : 76.90% ;
Human alphaherpesvirus 2
Lung-ATI : 92.69% ;
Lung-ATII : 85.05% ;
Lung-ATII : 80.89% ;
Lung-ATI : 80.00% ;
Lung-ATII : 79.86% ;
Rhinovirus C
Lung-Ciliated cells : 91.26% ;
Echovirus E1
Lung-Mac_alv : 91.01% ;
Lung-Cell_cycle : 90.11% ;
Lung-ATI : 84.52% ;
Lung-EC_lymph : 81.82% ;
Lung-Macrophages : 80.00% ;
Echovirus E8
Lung-Mac_alv : 91.01% ;
Lung-Cell_cycle : 90.11% ;
Lung-ATI : 84.52% ;
Lung-EC_lymph : 81.82% ;
Lung-Macrophages : 80.00% ;
Human parvovirus B19
Lung-Mac_alv : 91.01% ;
Lung-Cell_cycle : 90.11% ;
Lung-ATI : 84.52% ;
Lung-EC_lymph : 81.82% ;
Lung-Macrophages : 80.00% ;
Human metapneumovirus
Lung-Mac_alv : 91.01% ;
Lung-Cell_cycle : 90.11% ;
Lung-ATI : 84.52% ;
Lung-EC_lymph : 81.82% ;
Lung-Macrophages : 80.00% ;
Human betaherpesvirus 5
Lung-Mac_alv : 91.01% ;
Lung-Cell_cycle : 90.11% ;
Lung-ATI : 84.52% ;
Lung-EC_lymph : 81.82% ;
Lung-Macrophages : 80.00% ;
Lung-Secretory : 86.11% ;
Lung-Secretory : 85.28% ;
Lung-ATI : 84.95% ;
Lung-ATI : 83.87% ;
Lung-Secretory cells : 76.96% ;
Lung-Ciliated cells : 77.40% ;
Lung-Secretory cells : 75.76% ;
Mammalian orthoreovirus
Lung-Mac_alv : 91.01% ;
Lung-Cell_cycle : 90.11% ;
Lung-ATI : 84.52% ;
Lung-EC_lymph : 81.82% ;
Lung-Macrophages : 80.00% ;
Human gammaherpesvirus 4
Lung-Mac_alv : 91.01% ;
Lung-Cell_cycle : 90.11% ;
Lung-ATI : 84.52% ;
Lung-EC_lymph : 81.82% ;
Lung-Macrophages : 80.00% ;
Human rotavirus strain WA
Lung-Mac_alv : 91.01% ;
Lung-Cell_cycle : 90.11% ;
Lung-ATI : 84.52% ;
Lung-EC_lymph : 81.82% ;
Lung-Macrophages : 80.00% ;
Foot-and-mouth disease virus
Lung-Mac_alv : 91.01% ;
Lung-Cell_cycle : 90.11% ;
Lung-ATI : 84.52% ;
Lung-EC_lymph : 81.82% ;
Lung-Macrophages : 80.00% ;
Lung-Secretory : 86.11% ;
Lung-Secretory : 85.28% ;
Lung-ATI : 84.95% ;
Lung-ATI : 83.87% ;
Lung-Secretory cells : 76.96% ;
Lung-ATI : 82.58% ;
Lung-ATI : 80.21% ;
Lung-ATI : 76.90% ;
Hepacivirus C
Parietal-PL-EX-3 : 89.91% ;
Parietal-PL-IN-1 : 88.55% ;
Lung-Mac_alv : 87.50% ;
Occipital-OL-EX-5 : 87.42% ;
Parietal-PL-EX-4 : 86.57% ;
Lung-Mac_inter : 89.78% ;
Lung-B_Bcl11a+ : 80.85% ;
Occipital-OL-EX-5 : 75.50% ;
Lung-Cell_cycle : 86.81% ;
Lung-Mac_alv : 85.06% ;
Lung-Ciliated : 80.65% ;
Lung-Secretory : 78.17% ;
Lung-Ciliated cells : 77.82% ;
Lung-Peri : 80.00% ;
Lung-ATII : 75.29% ;
Lung-Ciliated cells : 77.40% ;
Lung-Secretory cells : 75.76% ;
Ebola virus
Lung-Mac_inter : 89.78% ;
Lung-Macrophages : 84.44% ;
Lung-Mac_alv : 80.03% ;
Lung-Mac_inter : 76.83% ;
Lung-Mac_alv : 82.77% ;
Lung-Peri : 76.00% ;
Marburg marburgvirus
Lung-Mac_inter : 89.78% ;
Lung-Macrophages : 84.44% ;
Lung-Mac_alv : 80.03% ;
Lung-Mac_inter : 76.83% ;
Lung-Mac_alv : 82.77% ;
Lung-Peri : 76.00% ;
Coxsackievirus B1
Occipital-OL-EX-2 : 88.64% ;
Occipital-OL-EX-5 : 88.08% ;
Occipital-OL-EX-3 : 86.54% ;
Occipital-OL-EX-4 : 83.20% ;
Occipital-OL-EX-1 : 83.04% ;
Lung-Secretory : 86.11% ;
Lung-Secretory : 85.28% ;
Lung-ATI : 84.95% ;
Lung-ATI : 83.87% ;
Lung-Secretory cells : 76.96% ;
Lung-ATI : 82.58% ;
Lung-ATI : 80.21% ;
Lung-ATI : 76.90% ;
Coxsackievirus B2
Occipital-OL-EX-2 : 88.64% ;
Occipital-OL-EX-5 : 88.08% ;
Occipital-OL-EX-3 : 86.54% ;
Occipital-OL-EX-4 : 83.20% ;
Occipital-OL-EX-1 : 83.04% ;
Coxsackievirus B3
Occipital-OL-EX-2 : 88.64% ;
Occipital-OL-EX-5 : 88.08% ;
Occipital-OL-EX-3 : 86.54% ;
Occipital-OL-EX-4 : 83.20% ;
Occipital-OL-EX-1 : 83.04% ;
Coxsackievirus B4
Occipital-OL-EX-2 : 88.64% ;
Occipital-OL-EX-5 : 88.08% ;
Occipital-OL-EX-3 : 86.54% ;
Occipital-OL-EX-4 : 83.20% ;
Occipital-OL-EX-1 : 83.04% ;
Coxsackievirus B5
Occipital-OL-EX-2 : 88.64% ;
Occipital-OL-EX-5 : 88.08% ;
Occipital-OL-EX-3 : 86.54% ;
Occipital-OL-EX-4 : 83.20% ;
Occipital-OL-EX-1 : 83.04% ;
Coxsackievirus B6
Occipital-OL-EX-2 : 88.64% ;
Occipital-OL-EX-5 : 88.08% ;
Occipital-OL-EX-3 : 86.54% ;
Occipital-OL-EX-4 : 83.20% ;
Occipital-OL-EX-1 : 83.04% ;
Human mastadenovirus A
Occipital-OL-EX-2 : 88.64% ;
Occipital-OL-EX-5 : 88.08% ;
Occipital-OL-EX-3 : 86.54% ;
Occipital-OL-EX-4 : 83.20% ;
Occipital-OL-EX-1 : 83.04% ;
Human mastadenovirus C
Occipital-OL-EX-2 : 88.64% ;
Occipital-OL-EX-5 : 88.08% ;
Occipital-OL-EX-3 : 86.54% ;
Occipital-OL-EX-4 : 83.20% ;
Occipital-OL-EX-1 : 83.04% ;
Lung-Secretory : 86.11% ;
Lung-Secretory : 85.28% ;
Lung-ATI : 84.95% ;
Lung-ATI : 83.87% ;
Lung-Secretory cells : 76.96% ;
Lung-B_Bcl11a+ : 82.98% ;
Human mastadenovirus D
Occipital-OL-EX-2 : 88.64% ;
Occipital-OL-EX-5 : 88.08% ;
Occipital-OL-EX-3 : 86.54% ;
Occipital-OL-EX-4 : 83.20% ;
Occipital-OL-EX-1 : 83.04% ;
Human mastadenovirus E
Occipital-OL-EX-2 : 88.64% ;
Occipital-OL-EX-5 : 88.08% ;
Occipital-OL-EX-3 : 86.54% ;
Occipital-OL-EX-4 : 83.20% ;
Occipital-OL-EX-1 : 83.04% ;
Human mastadenovirus F
Occipital-OL-EX-2 : 88.64% ;
Occipital-OL-EX-5 : 88.08% ;
Occipital-OL-EX-3 : 86.54% ;
Occipital-OL-EX-4 : 83.20% ;
Occipital-OL-EX-1 : 83.04% ;
Enterovirus A71
Lung-Ciliated cells : 87.85% ;
Lung-B_Bcl11a+ : 85.11% ;
Occipital-OL-EX-5 : 84.77% ;
Lung-Mac_inter : 82.26% ;
Occipital-OL-EX-1 : 81.88% ;
Coxsackievirus A16
Lung-Ciliated cells : 87.85% ;
Lung-B_Bcl11a+ : 85.11% ;
Occipital-OL-EX-5 : 84.77% ;
Lung-Mac_inter : 82.26% ;
Occipital-OL-EX-1 : 81.88% ;
Canine parvovirus
Lung-Cell_cycle : 86.81% ;
Lung-Mac_alv : 85.06% ;
Machupo mammarenavirus
Lung-Cell_cycle : 86.81% ;
Lung-Mac_alv : 85.06% ;
Guanarito mammarenavirus
Lung-Cell_cycle : 86.81% ;
Lung-Mac_alv : 85.06% ;
Mouse mammary tumor virus
Lung-Cell_cycle : 86.81% ;
Lung-Mac_alv : 85.06% ;
Argentinian mammarenavirus
Lung-Cell_cycle : 86.81% ;
Lung-Mac_alv : 85.06% ;
Feline panleukopenia virus
Lung-Cell_cycle : 86.81% ;
Lung-Mac_alv : 85.06% ;
Polytropic murine leukemia virus
Lung-Mac_alv : 86.13% ;
Occipital-OL-EX-5 : 85.43% ;
Lung-Macrophages : 81.60% ;
Lung-ATI : 80.15% ;
Occipital-OL-EX-2 : 77.02% ;
Xenotropic murine leukemia virus
Lung-Mac_alv : 86.13% ;
Occipital-OL-EX-5 : 85.43% ;
Lung-Macrophages : 81.60% ;
Lung-ATI : 80.15% ;
Occipital-OL-EX-2 : 77.02% ;
West Nile virus
Lung-Secretory : 86.11% ;
Lung-Secretory : 85.28% ;
Lung-ATI : 84.95% ;
Lung-ATI : 83.87% ;
Lung-Secretory cells : 76.96% ;
Coxsackievirus A9
Lung-Secretory : 86.11% ;
Lung-Secretory : 85.28% ;
Lung-ATI : 84.95% ;
Lung-ATI : 83.87% ;
Lung-Secretory cells : 76.96% ;
Lung-ATI : 82.58% ;
Lung-ATI : 80.21% ;
Lung-ATI : 76.90% ;
Human parechovirus 1
Lung-Secretory : 86.11% ;
Lung-Secretory : 85.28% ;
Lung-ATI : 84.95% ;
Lung-ATI : 83.87% ;
Lung-Secretory cells : 76.96% ;
Human gammaherpesvirus 8
Lung-Secretory : 86.11% ;
Lung-Secretory : 85.28% ;
Lung-ATI : 84.95% ;
Lung-ATI : 83.87% ;
Lung-Secretory cells : 76.96% ;
Human betaherpesvirus 6B
Lung-B_Jchain+ : 85.98% ;
Lung-Mac_alv : 83.54% ;
Feline immunodeficiency virus
Lung-B_Jchain+ : 85.98% ;
Lung-Mac_alv : 83.54% ;
Lung-Mac_alv : 76.22% ;
Lassa mammarenavirus
Lung-ATI : 84.52% ;
Lung-Mac_alv : 82.77% ;
Lung-Peri : 76.00% ;
Latino mammarenavirus
Lung-ATI : 84.52% ;
Oliveros mammarenavirus
Lung-ATI : 84.52% ;
Lymphocytic choriomeningitis mammarenavirus
Lung-ATI : 84.52% ;
Lung-Mac_alv : 82.77% ;
Lung-Peri : 76.00% ;
Zika virus
Lung-Mac_alv : 82.77% ;
Lung-Peri : 76.00% ;
Human mastadenovirus B
Lung-DC : 81.36% ;
Coxsackievirus A10
Lung-ATI : 80.95% ;
Human rhinovirus A2
Lung-Peri : 80.00% ;
Lung-ATII : 75.29% ;
Rhinovirus B14
Lung-Mac_inter : 79.03% ;
Lung-Mac_alv : 78.96% ;
Lung-ATI : 77.42% ;
Lung-DC : 76.27% ;
Lung-Mast : 75.51% ;
Coxsackievirus A21
Lung-Mac_inter : 79.03% ;
Lung-Mac_alv : 78.96% ;
Lung-ATI : 77.42% ;
Lung-DC : 76.27% ;
Lung-Mast : 75.51% ;
Human betaherpesvirus 7
Lung-B_Bcl11a+ : 78.72% ;
Simian immunodeficiency virus
Lung-B_Bcl11a+ : 78.72% ;
Human immunodeficiency virus 1
Lung-B_Bcl11a+ : 78.72% ;
Lung-Mac_alv : 76.22% ;
Human immunodeficiency virus 2
Lung-B_Bcl11a+ : 78.72% ;
Lung-Mac_alv : 76.22% ;
Simian sarcoma-associated virus
Lung-Mac_alv : 77.59% ;
Encephalomyocarditis virus
Lung-Mac_inter : 76.34% ;
Hepatitis E virus
Lung-ATI : 76.13% ;

Contact Us

E-mail: chendongsheng@genomics.cn

Address: Build 11, Beishan Industrial Zone, Yantian District, Shenzhen, 518083, China

Copyright © VThunter 2020-2021 ShenZhen, Guangdong province, China